The U.S. Food and Drug Administration (FDA) has granted accelerated approval for zongertinib (Hernexeos) a new targeted therapy for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. The expanded accelerated approval includes first line use as well as for patients who...
Want to know the latest news and articles posted on CancerConnect?
Then subscribe to their feed now! You can receive their updates by email, via mobile or on your personal news page on this website.
See what they recently published below.
Website title: CancerConnect - By combining information with a social community CancerConnect provides cancer patients and their caregivers a unique destination to seek information, support, and inspiration.